Edition:
India

Protagonist Therapeutics Inc (PTGX.OQ)

PTGX.OQ on NASDAQ Stock Exchange Global Market

18.56USD
20 Nov 2017
Change (% chg)

-- (--)
Prev Close
$18.56
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
34,911
52-wk High
$26.32
52-wk Low
$8.00

Select another date:

Thu, Nov 9 2017

BRIEF-Protagonist Therapeutics initiates phase 1 trial of oral peptide PTG-200

* Protagonist Therapeutics initiates phase 1 trial of oral peptide IL-23 receptor antagonist, PTG-200

BRIEF-Protagonist Therapeutics Q3 ‍net loss per share $0.29​

* Protagonist Therapeutics reports third quarter 2017 financial results and provides corporate update

BRIEF-Protagonist Therapeutics prices offering of 3.53 mln common shares at $17 per share

* Says public offering of 3.53 million common shares priced at $17.00 per share Source text for Eikon: Further company coverage:

BRIEF-Protagonist Therapeutics announces proposed public offering of common stock

* Protagonist Therapeutics announces proposed public offering of common stock

BRIEF-Protagonist Therapeutics Inc files for mixed shelf of up to $200 million - SEC filing ‍​

* Protagonist Therapeutics Inc files for mixed shelf of up to $200 million - SEC filing ‍​ Source text: (http://bit.ly/2xDBQBh) Further company coverage:

BRIEF-Protagonist Therapeutics announces closing of Janssen license

* Protagonist Therapeutics announces closing of Janssen license and collaboration agreement for PTG-200 and receipt of $50 million payment

BRIEF-Protagonist Therapeutics reports Q2 loss per share of $0.89

* Protagonist therapeutics reports second quarter 2017 financial results and business highlights

BRIEF-Protagonist Therapeutics appoints Five Prime Therapeutics CEO to board of directors

* Protagonist Therapeutics appoints Five Prime Therapeutics CEO, Lewis T. "Rusty" Williams, to its board of directors Source text for Eikon: Further company coverage:

BRIEF-Protagonist Therapeutics says will be responsible for conduct of Phase 1 clinical trial for PTG-200

* Protagonist Therapeutics Inc says co will be responsible, at its own expense, for conduct of Phase 1 clinical trial for PTG-200 - SEC filing

BRIEF-Protagonist Therapeutics signs deal with J&J to develop bowel drug

* Protagonist therapeutics enters into worldwide agreement with janssen to co-develop and commercialize ptg-200 for inflammatory bowel disease

Select another date: